alexa Movement disorders | Brazil | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Read more

Recommended Journals

Relevant Topics

Movement Disorders

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Movement disorders

    Pathophysiology:
    Movement disoreder caused by the disruption of any portion of this system can cause a person to produce movements that are too weak, too forceful, too uncoordinated, or too poorly controlled for the task at hand. Motor neurons transmit electrical signals that cause muscles to contract. An EMG translates these signals into graphs, sounds or numerical values that a specialist interprets. An EMG uses tiny devices called electrodes to transmit or detect electrical signals.

  • Movement disorders

    Statistics:
    The prevalence of all common categories of movement disorders was 28·0% (95% CI 25·9–30·1). Proportions in men (27·6% [95% CI 24·5–30·7]) and women (28·3% [25·5–31·2]) were closely similar and sharply increased with age (from 18·5% [15·0–22·0] in 50–59-year olds to 51·3% [44·9–57·7] in 80–89-year olds). Almost half of all patients (90/214) had moderate-to-severe disease expression, but only 7·0% (15/214) received standard drug treatment.

  • Movement disorders

    Treatment:
    Benzodiazepines or tricyclic antidepressants have been considered as therapeutic options in managing the disorder. Infantile and adolescent RMD respond well to low doses of clonazepam.

  • Movement disorders

    Major Research:
    Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of Parkinsonian Disorders and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings